UnknownNot applicableNCT05475691
Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscular Atrophy in Latin America
Studying Spinal Muscular Atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospital Israelita Albert Einstein
- Principal Investigator
- Otávio Berwanger, PhDHospital Albert Einstein
- Enrollment
- 361 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2022 – 2024
Study locations (18)
- Hospital Italiano de Buenos Aires, Buenos Aires, Buenos Aires F.D., Argentina
- Hospital de Pediatria J.P.Garrahan, Buenos Aires, Buenos Aires F.D., Argentina
- Private office, Buenos Aires, Rivadavia 4951 PB 2 Caballito, Argentina
- Clínica Universitaaria Reina Fabiola, Córdoba, Argentina
- Hospital Pediátrico Humberto Notti, Mendoza, Argentina
- HUPES - Escola Bahiana de Medicina e Saúde Pública, Salvador, Estado de Bahia, Brazil
- UFMG - Universidade Federal de Minas Gerais - Hospital das Clínicas, Belo Horizonte, Minas Gerais, Brazil
- Hospital Infantil Pequeno Príncipe, Curitiba, Paraná, Brazil
- Instituto de Puericultura e Pediatria Martagão Gesteira da UFRJ, Rio de Janeiro, Rio de Janeiro, Brazil
- HCPA - Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
- Unicamp - Hospital de Clínicas da Universidade Estadual de Campinas, Campinas, São Paulo, Brazil
- Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil
- Instituto da Criança do Hospital das Clínicas de São Paulo - FMUSP, São Paulo, São Paulo, Brazil
- Clínica Meds La Dehesa, Santiago, Chile
- Fundação Hospital da Misericórdia, Bogotá, Colombia
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05475691 on ClinicalTrials.govOther trials for Spinal Muscular Atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488338HABIT-ILE + FST in Children With SMA: Preliminary EffectivenessTeachers College, Columbia University
- RECRUITINGNCT07400198Gait and Bone Health in SMAJacqueline Montes
- RECRUITINGPHASE1, PHASE2NCT07070999Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1Gemma Biotherapeutics
- RECRUITINGNANCT07321977Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic VolunteersInstitut de Myologie, France
- RECRUITINGPHASE2NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophyargenx
- RECRUITINGNANCT07286565Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn ScreeningCentre Hospitalier Universitaire de Liege
- RECRUITINGNCT06532474Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed TherapiesSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT07265232Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).Lantu Biopharma